Choose a language and wait for the translated text.
Shots:
Grünenthal has entered into an agreement with Bayer to acquire Stivarga for ~€375M (~$430.67M), subject to customary closing conditions incl. regulatory approval, with the transaction expected to close by the end of 2026 or early 2027
Stivarga (regorafenib) is an oral multikinase inhibitor indicated for metastatic colorectal cancer, hepatocellular carcinoma, & gastrointestinal stromal tumours in pts previously treated with, or unable to receive, other available therapies
Stivarga is expected to lose exclusivity in 2029 in the EU and in 2030 in the US
Ref: PRnewswire  | Image: Grünenthal & Bayer  | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Grünenthal to Acquire Bayer’s Stivarga for ~€375M appeared first on PharmaShots.
